Atypical thrombotic and septic complications of totally implantable venous access devices in patients with cystic fibrosis.

Juan E Sola, M. M. Stone, B. Wise, P. M. Colombani

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The use of vascular access systems in patients with cystic fibrosis (CF) is well accepted, with lower overall complications and maintenance costs than percutaneous silastic catheters. We report our 6 year experience with 22 infusaports in 15 CF patients. Our patients had indwelling catheters for an average of 539 days per catheter (range, 14-2,224 days). These infusaports were used for home antibiotic therapy, blood sampling, and total parenteral nutrition. The overall complication rate was relatively low, 1 in every 1,483 catheter days. Infectious complications were extremely infrequent at a rate of 1 in 5,929 catheter days. The rate of mechanical complications was 1 in 1,976 catheter days. However, superior vena caval syndrome or deep venous thrombosis was associated with 3 of 22 catheters (13.6%). Due to this high incidence of major thrombotic events with the attendant risk of pulmonary embolism, all patients with CF using infusaports and without evidence of liver disease or bleeding problems receive aspirin prophylaxis.

Original languageEnglish
Pages (from-to)239-242
Number of pages4
JournalPediatric Pulmonology
Volume14
Issue number4
StatePublished - Dec 1 1992
Externally publishedYes

Fingerprint

Cystic Fibrosis
Catheters
Equipment and Supplies
Venae Cavae
Indwelling Catheters
Total Parenteral Nutrition
Pulmonary Embolism
Venous Thrombosis
Aspirin
Blood Vessels
Liver Diseases
Maintenance
Hemorrhage
Anti-Bacterial Agents
Costs and Cost Analysis
Incidence

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Atypical thrombotic and septic complications of totally implantable venous access devices in patients with cystic fibrosis. / Sola, Juan E; Stone, M. M.; Wise, B.; Colombani, P. M.

In: Pediatric Pulmonology, Vol. 14, No. 4, 01.12.1992, p. 239-242.

Research output: Contribution to journalArticle

@article{0885dea8af5743068e1bae99a3bb5766,
title = "Atypical thrombotic and septic complications of totally implantable venous access devices in patients with cystic fibrosis.",
abstract = "The use of vascular access systems in patients with cystic fibrosis (CF) is well accepted, with lower overall complications and maintenance costs than percutaneous silastic catheters. We report our 6 year experience with 22 infusaports in 15 CF patients. Our patients had indwelling catheters for an average of 539 days per catheter (range, 14-2,224 days). These infusaports were used for home antibiotic therapy, blood sampling, and total parenteral nutrition. The overall complication rate was relatively low, 1 in every 1,483 catheter days. Infectious complications were extremely infrequent at a rate of 1 in 5,929 catheter days. The rate of mechanical complications was 1 in 1,976 catheter days. However, superior vena caval syndrome or deep venous thrombosis was associated with 3 of 22 catheters (13.6{\%}). Due to this high incidence of major thrombotic events with the attendant risk of pulmonary embolism, all patients with CF using infusaports and without evidence of liver disease or bleeding problems receive aspirin prophylaxis.",
author = "Sola, {Juan E} and Stone, {M. M.} and B. Wise and Colombani, {P. M.}",
year = "1992",
month = "12",
day = "1",
language = "English",
volume = "14",
pages = "239--242",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Atypical thrombotic and septic complications of totally implantable venous access devices in patients with cystic fibrosis.

AU - Sola, Juan E

AU - Stone, M. M.

AU - Wise, B.

AU - Colombani, P. M.

PY - 1992/12/1

Y1 - 1992/12/1

N2 - The use of vascular access systems in patients with cystic fibrosis (CF) is well accepted, with lower overall complications and maintenance costs than percutaneous silastic catheters. We report our 6 year experience with 22 infusaports in 15 CF patients. Our patients had indwelling catheters for an average of 539 days per catheter (range, 14-2,224 days). These infusaports were used for home antibiotic therapy, blood sampling, and total parenteral nutrition. The overall complication rate was relatively low, 1 in every 1,483 catheter days. Infectious complications were extremely infrequent at a rate of 1 in 5,929 catheter days. The rate of mechanical complications was 1 in 1,976 catheter days. However, superior vena caval syndrome or deep venous thrombosis was associated with 3 of 22 catheters (13.6%). Due to this high incidence of major thrombotic events with the attendant risk of pulmonary embolism, all patients with CF using infusaports and without evidence of liver disease or bleeding problems receive aspirin prophylaxis.

AB - The use of vascular access systems in patients with cystic fibrosis (CF) is well accepted, with lower overall complications and maintenance costs than percutaneous silastic catheters. We report our 6 year experience with 22 infusaports in 15 CF patients. Our patients had indwelling catheters for an average of 539 days per catheter (range, 14-2,224 days). These infusaports were used for home antibiotic therapy, blood sampling, and total parenteral nutrition. The overall complication rate was relatively low, 1 in every 1,483 catheter days. Infectious complications were extremely infrequent at a rate of 1 in 5,929 catheter days. The rate of mechanical complications was 1 in 1,976 catheter days. However, superior vena caval syndrome or deep venous thrombosis was associated with 3 of 22 catheters (13.6%). Due to this high incidence of major thrombotic events with the attendant risk of pulmonary embolism, all patients with CF using infusaports and without evidence of liver disease or bleeding problems receive aspirin prophylaxis.

UR - http://www.scopus.com/inward/record.url?scp=0027031019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027031019&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 239

EP - 242

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 4

ER -